Source: International Congress 2017 – Airway disease and exacerbations
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Mohd Aminudin (shah alam, Malaysia). Baseline serum CCL5 as a predictor for loss of asthma control and exacerbation during step-wise treatment reduction.. 1129

Member's Comments

No comment yet.

Related content which might interest you: Elevated blood eosinophils on admission for a severe exacerbation of COPD is not a predictor for survival Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer Year: 2017 Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Low hematocrit as predictor of exacerbation frequency in COPD patients Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation Year: 2010 Patient baseline variables predict future asthma control status and risk of exacerbations Source: Annual Congress 2010 - Management of airway disease Year: 2010 Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Increased serum IL-17 is an independent risk factor for severe asthma Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity Year: 2008 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy Source: Eur Respir J 2002; 20: Suppl. 38, 141s Year: 2002 Sputum VEGF level increases with treatment of COPD acute exacerbation Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017 Is serum leptin level a predictor for asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 681s Year: 2005 The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005 Correlations between exacerbation rate and blood eosinophil levels in COPD patients Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Increased serum IL-17 does not predict future risk and impairment in asthma Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009 The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 Longitudinal measurement of airway inflammation relates to a higher risk of exacerbation in COPD. Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 The role of Hs-CRP in evaluating asthma severity and asthma control Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005